Despite the strong evidentiary examples supporting a pro-oncogenic role for GPER in breast cancer, it has been suggested that GPER does not drive cancer but may act as a “tumor suppressor”, with both genetic and pharmacological data reported in support of this label. The gene discussed is GPER1; the disease is neoplasm.